Alembic Pharmaceuticals informs about press release

13 Oct 2020 Evaluate

Alembic Pharmaceuticals has informed the exchange that its Associate Company, Rhizen Pharmaceuticals SA (Rhizen) has released a Press Release announcing that it has entered into an exclusive license agreement with Curon Biopharmaceutical for development and commercialization of Tenalisib, a Dual Pl3K Delta and Gamma Inhibitor for Oncology in Greater China. It has enclosed Rhizen's press release. Alembic Pharmaceuticals through its wholly owned subsidiary holds 50% ownership in Rhizen.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

880.60 -19.30 (-2.14%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×